Home World News Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients... World News Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer By Ogkologos - November 18, 2024 1012 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced... May 26, 2025 Mom Who Lost Child Donates Breast Milk To Mom With Cancer February 27, 2019 Multiple mRNA Vaccines Show Promise for Treating HPV-Related Cancers April 26, 2023 FDA Grants Regular Approval to Dostarlimab-gxly for dMMR Endometrial Cancer February 20, 2023 Load more HOT NEWS ESMO Launches Living Guidelines to Enhance the Usability of its Clinical... AI Model Identifies How Every Country Can Improve Its Cancer Outcomes Aiming to Prevent Cancer Cases, ESMO Calls Against Misleading Alcohol-Labelling Following... Efficacy of Dabrafenib Plus Trametinib in First-Line Treatment for Children and...
